Business
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective
About this update from Immunic, Inc.
[{"type":"text","content":"– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis –\n– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration of Bowel Architecture –\n– Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Fall of 2023 –\n– $77.3 Million in Cash, Cash Equivalents and Investments Expected to Fund Immunic Into the Fourth Quarter of 2024 –\n– Webcast to be Held Today, August 3, 2023, at 8:00 am ET –\nNEW YORK, Aug. 3, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.\n\"During the second quarter, we reported important clinical and preclinical data from our two, lead pipeline programs, including the most advanced drug candidate, vidofludimus calcium (IMU-838), as well as IMU-856,\" stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. \"Importantly, we announced publication, in the peer-reviewed Journal of Medicinal Chemistry, of preclinical evidence showing that vidofludimus calcium acts as a potent nuclear receptor related 1 (Nurr1) activator, which may be associated with both its hypothesized neuroprotective effects and the reduced disability-worsening events observed in multiple sclerosis (MS) patients. In the fall of this year, we expect to report an interim biomarker analysis of our phase 2 CALLIPER trial in progressive MS, designed to corroborate the neuroprotective potential of vidofludimus calcium, which could become a distinguishing factor in the MS market. Based on the substantial clinical activity seen thus far, along with the already known favorable safety and tolerability profile, we remain confident that vidofludimus calcium can potentially be a unique therapeutic approach for managing the multifaceted pathophysiology of MS.\"\nDr. Vitt continued, \"In May, we reported stronger than expected positive results from the...